King, J&J announce big buyouts

Two big deals hit the papers today: King Pharmaceuticals is taking over Alpharma, and Johnson & Johnson has inked an agreement to buy Omrix.  Together they amount to more than $2 billion in buyouts.

Let's take King's $1.6 billion deal first. As you know, the Tennessee company has been after Alpharma for several months, first with a $33-per-share offer and then, rebuffed, a $37-a-share bid. Alpharma wasn't thrilled about the higher offer, either, but shareholders tendered 73 percent of the outstanding stock anyway. King had threatened a proxy fight, but Alpharma finally gave in, saying it would support King's offer. The deal is expected to close by year's end.

Advantages to the King-Alpharma combo? Well, King thinks it can achieve some synergies and economies of scale by combining R&D and sales forces. Will we see an accompanying layoff of reps soon, then? Could be. We'll keep our eyes open.

And then there's J&J's $438 million purchase of Omrix Biopharmaceuticals. The deal adds more heft to J&J's surgical products unit Ethicon, which will take Omrix under its wing. The smaller company will continue to operate as a standalone unit, though. The $25-per-share purchase price is an 18 percent premium over Friday's $21 closing price for Omrix.

The J&J-Omrix combo marks another instance of one partner buying out another: J&J already has some distribution rights to Omrix's Evithrom and Evicel, and the two companies are working together on development of another surgical product.

- see the joint release from King and Alpharma
- check out the release from J&J
- read the New York Times article
- get the AP news

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.